This content is machine translated Neurodegenerative dementia Early diagnosis and effective therapy management in Alzheimer’s disease Alzheimer’s disease is the most common form of neurodegenerative disease in individuals over the age of 65 and is characterized by progressive dementia. The goal of current Alzheimer’s research is…
View Post 4 min This content is machine translated Multiple sclerosis Family planning with therapy need not be a challenge Multiple sclerosis (MS) predominantly affects women between the ages of 20 and 45 at the time of diagnosis – with an increasing incidence [1,2]. As a result, MS is the…
View Post 13 min This content is machine translated Quantitative sensory testing in neuropathic pain. Comprehensive functional analysis of the somatosensory nervous system Pain is one of the most difficult symptoms to detect. Many other signs of disease, such as skin symptoms or paralysis, are visible, palpable, and thus objectifiable. In the assessment…
View Post 3 min This content is machine translated Multiple sclerosis Current treatment strategies to halt progression. In most cases, multiple sclerosis is relapsing and can progress to a chronic progressive stage over time. Which therapy management is used depends not only on the individual circumstances but also…
View Post 3 min This content is machine translated Pediatric operations When children wish for more pain medication Postoperative pain and pain-related impairments are still inadequately treated in many cases, not only in adults but also in children. In an analysis of pediatric patient populations, a group of…
View Post 3 min This content is machine translated Parkinson's disease Effective therapy management: mastering challenges An effective treatment regimen in PD is closely linked to a personalized approach. Depending on the age of onset and subtype of the disease, the challenges are different. In addition…
View Post 6 min This content is machine translated KESIMPTA® (ofatumumab) for the treatment of relapsing-remitting multiple sclerosis High efficacy with good tolerability For patients with relapsing-remitting multiple sclerosis (RMS), KESIMPTA® (ofatumumab) has recently become the first subcutaneous antibody-based therapy option available. In the ASCLEPIOS I and II trials, ofatumumab was shown to…
View Post 5 min This content is machine translated Safety Check Selectivity as a distinguishing feature Like any form of intervention in the human immune system, therapy with Ozanimod carries certain risks. In particular, infections and adverse cardiac effects represent previously known side effects of treatment…
View Post 4 min This content is machine translated Efficacy Check Multiple levels of effectiveness The two completed phase III studies SUNBEAM [1] and RADIANCE [2] were able to demonstrate the efficacy of the new active substance in the area of other – radiological and…
View Post 5 min This content is machine translated Ozanimod A new player in MS therapy With the recently approved ozanimod, another potent compound for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS) is entering the Swiss market. The oral sphingosine-1-phosphate (S1P) receptor modulator demonstrated…
View Post 6 min This content is machine translated Diabetic polyneuropathy Measure nerve conduction velocity for diagnosis Diabetic polyneuropathy (dPNP) is the most common neuropathy in Western countries. But who gets them and how do you recognize them? This question is particularly important because 40% of those…
